Nevertheless, our findings indicated that FZHY or combined with ETV might be a better choice to improve the clinical efficacy, recover serum biomarkers of liver fibrosis (including HA and IV-C), and serum parameters for liver function (ALT, ALB, and TBil), lowered the total TCM symptom scores, relieved hypochondriac pain and poor appetite, regained the width of portal vein and thickness of spleen, and reduced the occurrence of adverse reactions. The gene discussed is ALB; the disease is Hepatic fibrosis.